CompletedPhase 3

Multicenter Trial of Immunotherapy With House Dust Mite Allergoid

Germany108 participantsStarted 2007-10

Plain-language summary

Multicenter Immunotherapy House Dust Mite Allergoid

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Positive SPT * Positive EAST * Positive specific provocation test Exclusion Criteria: * Serious chronic diseases * other perennial allergies

What they're measuring

The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline

Timeframe: November 2007 - February 2010

Trial details

NCT IDNCT00540631

SponsorAllergopharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-08

View on ClinicalTrials.gov More Rhinoconjunctivitis trials